ORASURE TECHNOLOGIES INC (OSUR) stock intrinsic value fair value estimate & owner earnings analysis

OraSure Technologies makes point-of-care and at-home diagnostic tests. Its flagship product is the OraQuick oral-fluid HIV test, which has FDA approval and World Health Organization prequalification and has been sold globally for two decades. The company also sells a hepatitis C test, a newer syphilis test, and a genomics and sample-collection business (saliva and other biospecimen collection kits used by research and pharmaceutical customers). Through 2025 it also sold InteliSwab, a rapid at-home COVID-19 test that was the company's largest revenue source during the pandemic under U.S. government procurement contracts. That COVID-19 business has now essentially disappeared, falling from $257 million in 2023 to $45 million in 2024 to just $0.6 million in 2025, and a separate, smaller substance-abuse testing line was discontinued at the end of 2024. Stripping those two away, the remaining business still declined in 2025: HIV testing revenue fell as U.S. and international government funding for HIV programs tightened, and the genomics collection business was hit by the bankruptcy of one large customer. Total company revenue fell 38% in 2025 to $115 million, and the company posted a net loss and negative operating cash flow for the year. In December 2024 the company acquired Sherlock Biosciences, a molecular-diagnostics developer, adding a pipeline of government-funded test programs, including a chlamydia/gonorrhea test now under FDA review. That acquisition increased research spending sharply in 2025 and is a real, but so-far unproven, source of future revenue. We added back depreciation, stock-based compensation, and other non-cash charges exactly as the company reported them, and we based future capital-spending needs on actual cash equipment spending, since revenue has been shrinking rather than growing. The last two full years, 2024 and 2025, are the cleanest picture of the business as it exists today, after the pandemic surge and unwind and following the Sherlock purchase, and both years showed a loss on a cash basis once stock-based pay and equipment spending are subtracted from operating cash flow. We started our forecast from that loss rather than assuming an immediate turnaround. The early-2026 numbers we have seen are mixed: revenue continued to soften in the first quarter before nearly stabilizing in the second, and reported net income swung from a loss in the first quarter to a small profit in the second. That is not yet a clear, consistent trend, so we treated it as tentative evidence that the sharpest declines are behind the company rather than as proof the business has turned the corner. In our base case, funding pressure on HIV testing continues for several more years before leveling off, the genomics business holds roughly steady at its post-bankruptcy size, and Sherlock-related research spending stays elevated for a few years before easing. On this path, cash losses narrow gradually and the business reaches roughly breakeven within four to five years, settling into modest, sustained profitability supported by the HIV test's long-standing regulatory approvals and market position. We do not assume the Sherlock pipeline succeeds commercially in this case, since it has not yet cleared regulatory review. In our bear case, HIV program funding cuts deepen rather than level off, the genomics business does not find a replacement for its lost customer, and Sherlock-related research spending continues for years without a commercial product to show for it. Under this path the company keeps losing cash for the next decade; losses narrow somewhat as costs are cut but never turn to a profit within our forecast period. Valued purely on the cash the business itself would generate, this case is worth less than zero per share, meaning that absent a turnaround, continuing to fund the business would cost shareholders more than it would return them. The company is debt-free and holds meaningful cash today, which buys it years of room to prove otherwise, but that cash cushion is not part of this per-share estimate. In our bull case, HIV funding stabilizes, the genomics business recovers modestly, and the one concrete near-term catalyst we can point to plays out: the Sherlock chlamydia/gonorrhea test now under FDA review is cleared and launched successfully, adding a new, higher-margin revenue stream on top of a stabilized legacy business. In this case the company returns to solid, sustained profitability within three to four years. Because the base and bear outcomes are close together and the gap between them depends on funding and competitive developments outside the company's control, the margin-of-safety price sits at a substantial discount to our base-case estimate, and it assumes either the Sherlock test clears the FDA or two or three more quarters confirm that revenue and cash losses have genuinely stabilized. One item we could not fully reconcile line-by-line from the filings: a small number of cash-flow reconciling items are not labeled identically across filing years; where this occurred we relied on the total reported cash flow from operations, which is unaffected and ties out in every year we checked.